New Agents in Chronic Lymphocytic Leukemia: A Practical Guide

New Agents in Chronic Lymphocytic Leukemia: A Practical Guide

Episodes

Specialty:

All

Year:

All

EP. 1: Prognostic Factors and the Impact of New Therapies

January 19th 2016

EP. 2: Detecting Chromosomal Abnormalities in CLL

January 19th 2016

EP. 3: Front-Line Chemoimmunotherapy in CLL

January 19th 2016

EP. 4: Clinical Objectives in Chronic Lymphocytic Leukemia Treatment

January 19th 2016

EP. 5: The Value of CT Scans in Chronic Lymphocytic Leukemia

January 19th 2016

EP. 6: Chemoimmunotherapy in Chronic Lymphocytic Leukemia

January 19th 2016

EP. 7: CD-20 Antibodies in Chronic Lymphocytic Leukemia

January 19th 2016

EP. 8: The Role of Ofatumumab in the Treatment of CLL

January 19th 2016

EP. 9: Small-Molecule Inhibitors: Ibrutinib in CLL

January 19th 2016

EP. 10: Using Ibrutinib in Chronic Lymphocytic Leukemia

January 19th 2016

EP. 11: Pharmacovigilance with Ibrutinib in CLL

January 19th 2016

EP. 12: Mechanisms of Ibrutinib Resistance in CLL

January 19th 2016

EP. 13: Evaluating the Role of Idelalisib in CLL

January 19th 2016

EP. 14: Venetoclax in Chronic Lymphocytic Leukemia

January 19th 2016

EP. 15: Emerging Chronic Lymphocytic Leukemia Therapies

January 19th 2016

Trending on OncLive

Five Under 5: Top Oncology Videos for the Week of 8/31/26

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

The OncFive: Top Oncology Articles for the Week of 8/30